MD Anderson and Esperance Pharmaceuticals enter strategic alliance

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

MD ANDERSON CANCER CENTER and Esperance Pharmaceuticals Inc. entered into a strategic alliance to accelerate the clinical development of its lead anti-cancer candidate, EP-100, for the treatment of ovarian cancer, and to collaborate on preclinical studies of EP-100 as a treatment for breast cancer.

At the 2015 ASCO Annual Meeting, the company reported positive results from a phase II trial of EP-100 in ovarian cancer patients resistant to paclitaxel. EP-100 is a targeted membrane-disrupting peptide designed to seek and destroy cancer cells that overexpress luteinizing hormone releasing hormone receptors on their surfaces. LHRH receptors are over-expressed in a wide range of cancers including ovarian, breast, prostate, pancreatic and endometrial cancer.

MD Anderson will conduct additional studies to help prepare for a phase III trial of EP-100 in ovarian cancer, including more fully elucidating its mechanism of action and identifying potential biomarkers to support the selection of those patients most likely to respond to the drug.

It also will collaborate with Esperance to conduct studies needed to initiate clinical trials of EP-100 in breast cancer and assess the anti-cancer potential of other drug candidates generated by Esperance’s Cationic Lytic Peptide platform technology. Further details of the agreement were not disclosed.

YOU MAY BE INTERESTED IN

Candace S. Johnson leads America’s oldest cancer research center and Jonathan W. Friedberg leads the newest NCI-designated center. Their catchment areas are contiguous, their faculty and staff members collaborate often, and together their institutions embody the culture of NCI-designated cancer centers. 

In the first meeting of the National Cancer Advisory Board since the inauguration of President Donald Trump, NCI Principal Deputy Director Douglas R. Lowy addressed many of the burning questions the oncology field has for the institute. On indirect costs: NCI will continue to use previously negotiated and approved indirect cost rates, with the exception...

The Cancer Letter staff were finalists for nine 2025 Dateline Awards from the Washington, D.C. Chapter of the Society of Professional Journalists—seven for journalism; two for design—and won first place for four. The Cancer Letter’s entries recognized by SPJ include investigative journalism, series, breaking news, features, photojournalism, commentary, illustration, and front page design. This is...

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login